je.st
news
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
Category:Biotechnology and Pharmaceuticals